Comparative Pharmacology
Head-to-head clinical analysis: DROXIDOPA versus VAZCULEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROXIDOPA versus VAZCULEP.
DROXIDOPA vs VAZCULEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Droxidopa is a synthetic precursor of norepinephrine that increases norepinephrine levels in the peripheral nervous system, thereby improving sympathetic tone and blood pressure regulation.
Vazculep is a direct-acting vasoconstrictor that stimulates alpha-adrenergic receptors in vascular smooth muscle, causing peripheral vasoconstriction and increased blood pressure.
100-200 mg orally three times daily, with a maximum of 600 mg three times daily if needed.
5 mg IV bolus followed by 2.5 mg/hour continuous IV infusion; titrate to mean arterial pressure ≥65 mmHg. Maximum infusion rate: 40 mg/hour.
None Documented
None Documented
2–3 hours; terminal half-life approximately 2.5 hours, requiring 3–4 times daily dosing to maintain plasma levels.
Clinical Note
moderateDroxidopa + Torasemide
"Droxidopa may increase the hypokalemic activities of Torasemide."
Clinical Note
moderateDroxidopa + Etacrynic acid
"Droxidopa may increase the hypokalemic activities of Etacrynic acid."
Clinical Note
moderateDroxidopa + Furosemide
"Droxidopa may increase the hypokalemic activities of Furosemide."
Clinical Note
moderateDroxidopa + Bumetanide
"Droxidopa may increase the hypokalemic activities of Bumetanide."
Terminal elimination half-life is 12 hours. In patients with moderate renal impairment (CrCl 30-50 mL/min), half-life increases to 24 hours. Dose adjustment is recommended for CrCl <30 mL/min.
Renal: ~75% as unchanged drug and metabolites (including 3-O-methyldroxidopa and other conjugates); biliary/fecal: minimal (<5%).
Renal excretion of unchanged drug accounts for 70% and fecal/biliary excretion accounts for 30%. Approximately 15% of the dose is excreted as glucuronide conjugate in urine.
Category C
Category C
Vasopressor
Vasopressor